Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03655236 · ClinicalTrials.gov registry record · Phase 2
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
A Phase 2 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Terminated
- Registry status
- Phase 2
- Development phase
- 513
- Enrollment target
NCT03655236 is a Phase 2 study that was terminated before completion, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 513 participants.
The verdict
NCT03655236, a Phase 2 study, was terminated before completion, sponsored by Sun Pharma Advanced Research Company Limited.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 513 participants
- Enrollment target
Study Summary
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for subjects who have completed week 40 of Part 1
Interventions
- OTHER placebo
- DRUG K0706
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 513 participants |
| Start Date | 2019-02-18 |
| Est. Completion | 2024-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03655236
The ClinicalTrials.gov registry entry for NCT03655236 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 513 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT03655236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03655236 about?
NCT03655236 is a clinical study titled "PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706". This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for sub...
What is the current status of trial NCT03655236?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 513 participants. The study started on 2019-02-18. Estimated completion is 2024-06-06.
What interventions are being tested in trial NCT03655236?
The interventions under investigation include: placebo (OTHER), K0706 (DRUG).
Who is sponsoring clinical trial NCT03655236?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.